Stenoparib (2X-121)

About Allarity Therapeutics

Allarity Therapeutics is a Danish clinical-stage biotech focused on personalizing cancer care by integrating its proprietary Drug Response Predictor (DRP®) diagnostic platform with targeted therapeutics. Its strategy centers on advancing stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer, using a DRP® companion diagnostic to select patients most likely to respond. The company has achieved FDA Fast Track designation for stenoparib and is executing a focused Phase 2 trial, positioning it as a high-risk, high-reward player in precision oncology.

Therapeutic Areas